Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shingrix + quadrivalent influenza vaccine refers to the concomitant administration of the recombinant adjuvanted zoster vaccine Shingrix with an inactivated quadrivalent influenza vaccine (commonly Fluarix Quadrivalent), given as two separate intramuscular injections during the same visit to prevent herpes zoster and seasonal influenza in adults. Shingrix contains varicella zoster virus glycoprotein E antigen combined with the AS01B adjuvant system, which enhances cell-mediated and humoral immunity against varicella zoster virus, while quadrivalent influenza vaccines contain split or recombinant hemagglutinin antigens from two influenza A subtypes and two influenza B lineages to induce strain-specific neutralizing antibodies.[5][7][11] Coadministration studies have shown that immune responses and overall safety profiles are generally preserved when these vaccines are given together, supporting their concurrent use to improve adult vaccination coverage.[5][7][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shingrix + quadrivalent influenza vaccine.